Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide
Eli Lilly started building a 3.5 billion dollar injectables and device site in Fogelsville, due to run by 2031. Its first named product, the triple hormone peptide retatrutide, is still in Phase 3 trials.
What's new
Eli Lilly broke ground on a 3.5 billion dollar injectable medicine and device site in Fogelsville, Pennsylvania, first announced in February 2026, with about 850 permanent jobs planned.
Why it matters
The plant is built to make next generation obesity drugs, led by retatrutide, a triple hormone peptide that is still in Phase 3 trials and not approved anywhere.
What's next
Lilly expects the site to be running by 2031. No retatrutide filing date has been announced, so approval and demand remain open questions.
Eli Lilly broke ground on 12 November on a 3.5 billion dollar site for injectable medicines and devices in Fogelsville, in Pennsylvania's Lehigh Valley. The Lilly Pennsylvania plant is meant to add capacity for next generation obesity drugs, and the first product the company names is retatrutide, a triple hormone peptide that no regulator has approved. Lilly expects the site to be running by 2031. The company said the project will bring about 850 permanent jobs and roughly 2,000 construction jobs.
What Lilly is building in Fogelsville
The site sits in Upper Macungie Township. Lilly first picked Pennsylvania for the project in early February 2026, when trade press reported the same 3.5 billion dollar figure and a production start in 2031, so the November ceremony marks the start of construction rather than a new commitment. According to the company release, the Lilly Pennsylvania plant will make injectable medicines and the devices that deliver them. Lilly says each production run will pass through more than 5,000 documented steps and that every unit will be imaged and inspected more than 70 times. The company also plans to rely on machine learning, digital controls and data analytics, and it is aiming for LEED Gold certification for the building. None of these process claims can be checked from outside before the plant starts work.
Lilly chair and chief executive David A. Ricks framed the project around demand. "Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly," he said in the release. Pennsylvania Governor Josh Shapiro and Senator Dave McCormick welcomed the investment, and township board chair Jeff Fleischaker spoke for local officials. Lilly also pledged up to 1 million dollars over five years to the Upper Macungie Township Community Fund for a program on nutrition, fresh food access and healthy living. The release describes the permanent roles as engineers, scientists, operations staff and lab technicians. It does not give a hiring timeline, the number of production lines or the yearly output the site is designed to reach.
Built for a drug still in trials
Retatrutide is a single peptide molecule that activates three hormone receptors: GIP, GLP 1 and glucagon. In its trials it is given once a week by injection. Lilly states that the molecule is investigational and may not be legally sold or marketed for human use. Its Phase 3 program covers obesity or overweight with a related condition, type 2 diabetes, knee osteoarthritis pain, moderate to severe obstructive sleep apnea, chronic low back pain, cardiovascular outcomes and fatty liver disease linked to metabolic dysfunction. In December 2025 the first Phase 3 retatrutide readout reported the largest average weight loss seen so far in such a trial. The groundbreaking release gives no filing date, and no regulator has set a decision date.
Building the plant before approval means Lilly carries the risk that the drug fails, is delayed or reaches a smaller market than planned.
Lilly is therefore putting up injectable manufacturing capacity before any regulator has ruled on the drug it names first. Pharmaceutical Executive, in its weekly industry roundup, argued that manufacturing capacity, more than the science, now limits how fast new obesity drugs reach patients. That is the magazine's reading, not a company statement. Building the plant before approval means Lilly carries the risk that the drug fails, is delayed or reaches a smaller market than planned. The company describes the site as serving next generation obesity medicines in general, so it is not tied to a single molecule. The 2031 start date also means the plant will not ease any obesity drug supply pressure for several years.
Ten new US sites since 2020
The Lilly Pennsylvania plant is one of 10 new US manufacturing sites the company has announced since 2020, and Lilly places it within a 50 billion dollar push to expand domestic medicine production. Five of the sites make active pharmaceutical ingredients, the drug substance itself. Four, including Fogelsville, fill and assemble injectable medicines and devices. One, in Lebanon, Indiana, is devoted to genetic medicines. The table groups the sites as Lilly's release lists them. One of the two ingredient sites in Lebanon is the Lilly Medicine Foundry, which the company says will work on new production methods and on medicines for clinical trials. The release does not split the 50 billion dollar total by site, so the amount going to each plant beyond Fogelsville is not public.
| Site type | Number | Locations named by Lilly |
|---|---|---|
| Active pharmaceutical ingredients | 5 | Richmond VA, Huntsville AL, Houston TX, two in Lebanon IN |
| Injectable medicines and devices | 4 | Research Triangle Park NC, Concord NC, Kenosha WI, Fogelsville PA |
| Genetic medicines | 1 | Lebanon IN |
For peptide medicines both halves of the chain matter. A peptide is first made as drug substance at an ingredient plant and is then filled into pens or vials under sterile conditions at sites like the one now under way in the Lehigh Valley. During the US shortages of semaglutide and tirzepatide, which the FDA listed from 2022 until late 2024 and early 2025, compounded copies spread, and the agency moved to wind them down once supply recovered. Extra fill and device capacity is one way large makers try to avoid a repeat. Whether it is enough depends on demand that nobody can forecast with confidence, including how many health plans pay for obesity drugs. Recent federal rules, such as the FEHB behavioral therapy requirement, show that coverage can tighten as well as widen.
What comes next for the site
Lilly gives few milestones between now and 2031. The company expects construction to employ about 2,000 workers through build and startup, and the permanent staff of about 850 to follow as the site approaches production. Pennsylvania officials have presented the project as a gain for the state's life sciences sector, while Lilly's release does not mention any public incentives, so none are reported here. For readers following the drug rather than the building, the markers that matter come earlier. They include a regulatory filing for retatrutide, outcome data from its longer trials such as the cardiovascular study, and any further change in how the FDA treats compounded copies of approved obesity peptides once branded supply is ample.
Plants like Fogelsville also matter for safety. Medicines made under FDA oversight carry batch records, inspection data and an approved label, and products sold online as research peptides carry none of that. Lilly says retatrutide cannot be legally sold or marketed for human use, so any product offered under that name outside a registered clinical trial is unapproved and of unknown content. The new plant does not change that before approval. Legitimate access today runs only through enrolment in Lilly's trials, which are listed on public registries such as ClinicalTrials.gov. Further coverage of plants, deals and pricing in peptide medicine sits on the industry desk, which tracks how capacity plans like this one turn into supply.
Conclusion
The Lilly Pennsylvania plant is a construction start on a site first announced in February, with production planned for 2031. Its headline product, retatrutide, remains investigational, so the 3.5 billion dollar outlay is a bet on approvals that have not happened. The facts that will decide its value, from trial outcomes to regulatory decisions and insurance coverage of obesity drugs, are still ahead.